← Leaderboards
Bert J. W. M. Oehlen
Angion Biomedica Corporation
$7,885,442
Attributed
$7,885,442
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2008–17$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$7,885,442 · 12
By mechanism
R44$5,461,907 · 3
R43$2,423,535 · 9
Top collaborators
No co-investigators on record.
Most similar at Angion Biomedica Corporation
Same institution · by research overlap
- David E Smith$8,398,075
- Youzhi Tong$426,946
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadPre-ClinicalIn VitroIn VivoSeriesRattusPharmaceutical PreparationsInhibitor/AntagonistGrantDoseAnimal ModelOralAnimalsEnzymesLungDesignSmall MoleculeBasePropertyUnited StatesPublic Health RelevanceMouse ModelSamplingCause Of Death
Grant awards (15)
Aldosterone Synthase Inhibitor for CKD$709,140
R44 · FY2017 · DK · contact PI
Steroid 11β-hydroxylase inhibitor for Cushing's Syndrome$222,670
R43 · FY2017 · DK · contact PI
Aldosterone Synthase Inhibitor for CKD$610,943
R44 · FY2016 · DK · contact PI
Aldosterone Synthase Inhibitor for CKD$380,911
R43 · FY2013 · DK · contact PI
LPA1 antagonist for alcoholic liver disease$251,048
R43 · FY2013 · AA · contact PI
Treatment for alcoholic liver disease$1,223,250
R44 · FY2012 · AA · contact PI
Retinoic Acid Modulation for Scleroderma$298,114
R43 · FY2012 · AR · contact PI
Treatment for alcoholic liver disease$829,090
R44 · FY2011 · AA · contact PI
Therapeutic use of small-molecule HGF-mimetic for emphysema$954,039
R44 · FY2010 · HL · contact PI
PDGFR and KDR Inhibitors for Liver Fibrosis$269,786
R43 · FY2010 · DK · contact PI
Treatment for alcoholic liver disease$238,482
R43 · FY2010 · AA · contact PI
Therapeutic use of small-molecule HGF-mimetic for emphysema$1,135,445
R44 · FY2009 · HL · contact PI
Novel therapeutic for Alcoholic Liver Disease$327,272
R43 · FY2009 · AA · contact PI
Therapeutic Potential of a Small Molecule Compound for Emphysema$234,658
R43 · FY2008 · HL · contact PI
Anti-Angiogenic and Tumorcidal Drugs Against Lung Carcinoma$200,594
R43 · FY2008 · CA · contact PI